300642 Stock Overview
Researches and develops, manufactures, and distributes IVDs in China and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
Tellgen Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥14.15 |
52 Week High | CN¥19.82 |
52 Week Low | CN¥9.94 |
Beta | 0.36 |
11 Month Change | 25.67% |
3 Month Change | 0.71% |
1 Year Change | -27.14% |
33 Year Change | -53.69% |
5 Year Change | -36.23% |
Change since IPO | -26.50% |
Recent News & Updates
Shareholder Returns
300642 | CN Medical Equipment | CN Market | |
---|---|---|---|
7D | 22.2% | -0.8% | -0.3% |
1Y | -27.1% | -14.6% | -18.1% |
Return vs Industry: 300642 underperformed the CN Medical Equipment industry which returned -16.2% over the past year.
Return vs Market: 300642 underperformed the CN Market which returned -19% over the past year.
Price Volatility
300642 volatility | |
---|---|
300642 Average Weekly Movement | 8.1% |
Medical Equipment Industry Average Movement | 5.1% |
Market Average Movement | 5.6% |
10% most volatile stocks in CN Market | 8.9% |
10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 300642 has not had significant price volatility in the past 3 months.
Volatility Over Time: 300642's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 574 | Jian Er Yao | www.tellgen.com |
Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer and HPV testing kits; Y chromosome microdeletions test kits; autoimmune; cardiovascular and inflammation; biochemistry kits; DNA methylation testing kits; and molecular detection of COVID-19 and others. It also provides diagnostic reagents/testing instruments and assembly lines.
Tellgen Corporation Fundamentals Summary
300642 fundamental statistics | |
---|---|
Market cap | CN¥2.29b |
Earnings (TTM) | CN¥73.79m |
Revenue (TTM) | CN¥514.04m |
31.1x
P/E Ratio4.5x
P/S RatioIs 300642 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
300642 income statement (TTM) | |
---|---|
Revenue | CN¥514.04m |
Cost of Revenue | CN¥173.85m |
Gross Profit | CN¥340.18m |
Other Expenses | CN¥266.40m |
Earnings | CN¥73.79m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 27, 2024
Earnings per share (EPS) | 0.46 |
Gross Margin | 66.18% |
Net Profit Margin | 14.35% |
Debt/Equity Ratio | 0.4% |
How did 300642 perform over the long term?
See historical performance and comparison